Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Latest Information Update: 20 May 2024
At a glance
- Drugs Bavituximab (Primary) ; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 19 Oct 2023 Status changed from active, no longer recruiting to completed.
- 16 Jun 2023 Results published in the Clinical Cancer Research
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology